Journal Mobile Options
Table of Contents
Vol. 72, No. 3, 2004
Issue release date: April 2004

Neoadjuvant Hormone Treatment with Leuprolide Acetate Depot 3.75 mg and Cyproterone Acetate, before Radical Prostatectomy: A Randomized Study

Prezioso D. · Lotti T. · Polito M. · Montironi R.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objectives: To assess the effect of neoadjuvant hormone treatment before radical prostatectomy on: tumor/prostate volume, prostate-specific antigen (PSA) and testosterone levels, surgical margin status and tumor stage, and the ease of surgery following treatment. Methods: Patients with clinically localized prostatic carcinoma were randomized to receive leuprolide acetate depot 3.75 mg once a month for 3 months and cyproterone acetate 300 mg once a week for 3 weeks prior to surgery (group A). A control group of patients had surgery without any pretreatment (group B). Results: 167 patients were evaluated for the efficacy parameters. In group A, 31% of patients had a reduction in tumor/prostate volume following hormone therapy. PSA and testosterone levels were significantly reduced (p = 0.0001) in patients in group A compared to basal values. Centralized histopathological data evaluated in 145 patients (group A and 75 group B) showed that more patients in group B had tumors at stages T3A and T3B than in group A; this difference was close to significance (p = 0.057). Positive surgical margins were more common in group B (60% of patients) compared to group A (39% of patients). Similarly lymph node involvement was more common in group B compared to group A (11 versus 3%). There was little difference between the 2 study groups for the other surgical parameters assessed (ease of dissection, duration of surgery, blood loss). Conclusions: Neoadjuvant hormone therapy before radical prostatectomy has some effects in the treatment of prostate cancer. However, long-term follow-up of patients is needed to assess the impact of this therapy on morbidity and mortality.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Hamdy FC, Thomas BG: New therapeutic concepts in prostate cancer. BJU Int 2001;88:43–48.
  2. Iselin CE, Robertson JE, Paulson DF: Radical perineal prostatectomy: Oncological outcome during a 20-year period. J Urol 1999;161:163–168.
  3. Scolieri MJ, Altman A, Resnick MI: Neoadjuvant hormonal ablative therapy before radical prostatectomy: A review. Is it indicated? J Urol 2000;164:1465–1472.
  4. Labrie F, Gomez JL, Cusan L, Diamond P, Fradet Y, Têtu B, et al: Neoadjuvant antiandrogen therapy for localized prostate cancer. Prospective and randomized clinical trial. J Endocrinol Invest 1994;17:61.
  5. Kennedy TJ, Sonneland AM, Martlett MM, Troup RH: Luteinizing hormone-releasing hormone downstaging of clinical stage C prostate cancer. J Urol 1992;147:891–893.
  6. Bourdin S, Karam G, Clemain P, Bouchot O, Peuvrel P, Lacoste J, et al: Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer. J Int Med Res 1990;18:74–78.

    External Resources

  7. Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, et al: Neoadjuvant hormonal therapy: The Canadian experience. Urology 1997;49:56–64.
  8. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 1995;154:424–428.
  9. Hugosson J, Abrahamsson PA, Ahlgern G, Aus G, Lundberg S, Schelin S, et al: The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1996;29:413–419.
  10. Witjes WP, Schulman CC, Debruyne FM: Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. Urology 1997;49:65–69.
  11. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–424.
  12. Armas OA, Melamed A, Aprikian A, Cordon-Cardo C, Fair W, Reuter WE: Effect of preoperative androgen deprivation therapy in prostatic carcinoma. Lab Invest 1993;68:55A.
  13. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF: The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer 1993;71(suppl):1031–1038.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50